Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Lehmann

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Urologic Oncology|May 17, 2023
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trialJulia Heinzelbecker, Natalie Spieler, Michael Kuehn, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
European Urology|September 18, 2025
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical CystectomyMatthias Michael Heck, Jan Lehmann, Thomas Amiel, et al.
European Urology|December 9, 2008
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)Jan Lehmann, Henrik Suttmann, Peter Albers, et al.
European Urology Oncology|October 9, 2023
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)]Markus Eckstein, Christian Matek, Paul Wagner, et al.
European Urology Oncology|August 10, 2023
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient OutcomesMarkus Eckstein, Christian Matek, Paul Wagner, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Urologic Oncology|May 17, 2023
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trialJulia Heinzelbecker, Natalie Spieler, Michael Kuehn, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
European Urology|September 18, 2025
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical CystectomyMatthias Michael Heck, Jan Lehmann, Thomas Amiel, et al.
European Urology|December 9, 2008
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)Jan Lehmann, Henrik Suttmann, Peter Albers, et al.
European Urology Oncology|October 9, 2023
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)]Markus Eckstein, Christian Matek, Paul Wagner, et al.
European Urology Oncology|August 10, 2023
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient OutcomesMarkus Eckstein, Christian Matek, Paul Wagner, et al.
Pageof 6